JCAS Rec'd PCT/PTO 1 4 FEB 2001

PATENT

DOCKET NO. BM45330

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PCT/DO-EO

هر لار

Commissioner for Patents Washington, D.C. 20231

"Express Mail" mailing label number EK 295 392 146 US

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 CFR § 1.10 on the date indicated above and addressed to: Commissioner of Patents, Washington, DC 20231, on February 14, 2001.

Colleen Hanagan

NATIONAL STAGE APPLICATION TRANSMITTAL LETTER APPLICATION FILING UNDER 35 U.S.C. § 371

Transmitted herewith for filing is the patent application of:

Inventor(s)/Applicant(s): Thonnard, Joelle International Application No.: PCT/EP99/05989

International Published Appln. No.: WO 00/11182

International Filing Date: 13 August 1999 Priority Filing Date: 18 August 1998

Thirty Month Date: 18 February 2001

Title: "BASB024 OUTER MEMBRANE PROTEIN

OF NEISSERIA MENINGITIDIS"

1. THIS NEW APPLICATION IS A <u>NATIONAL STAGE</u>
<u>APPLICATION UNDER PCT, CHAPTER II</u> WITH A REQUEST FOR EXAMINATION WITHOUT DELAY TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US).

\boxtimes	This is a FIRST submission of items concerning a filing under 35 U.S.C. §
	371;

This is a **SECOND** or subsequent submission of items concerning a filing under 35 U.S.C. § 371.

2. This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).


528 Rec'd P DOCKET NO. BM45330

3. month		per Demand for International Preliminary Examination was made by the 19 TH are earliest claimed priority date.					
4. 1.495(Enclosed items are required for filing under 37 CFR § 1.53(b) and § 1.494(b) or § (b):						
	\boxtimes	One copy of International Publication WO 00/11182					
	(a)	is transmitted herewith (required only if not transmitted by the International Bureau)					
	(b)	has been transmitted by the International Bureau					
	(c)	is not required, as the application was filed in the United States Receiving Office (RO/US)					
<u>Fees</u>							
	⊠ nation F \$860.00	The basic national fee set forth in 37 CFR § 1.482 - International Preliminary Fee not paid to USPTO but International Search Report prepared by the EPO or					
	\boxtimes	Claims in Excess of 20 (20 @ \$18.00)					
	\boxtimes	Independent Claims in Excess of 3 (4 @ \$80.00)					
5.	Further	Further enclosed are:					
	\boxtimes	One copy of International Preliminary Examination Report.					
	\boxtimes	One copy of International Search Report - (references not available).					
		One copy of Written Opinion.					
		One copy of PCT Request as filed.					
		One copy of Chapter II Demand as filed.					
6. 371(c)	(2))	A translation of the International Application into English (35 U.S.C. §					
7. 19 (35	U.S.C.	Amendments to the claims of the International Application under PCT Article . § 371(c)(3))					
8. U.S.C.	\$ 371(d	A translation of the amendments to the claims under PCT Article 19 (35 § 371(c)(3))					
9.	Still additional papers enclosed:						
		Assignment with Assignment Recordation Form Cover Sheet					
		Verification Statement Claiming Small Entity Status					
	$\overline{\Box}$	Declaration or oath is enclosed executed by the inventor					
	$\overline{\Box}$	An Information Disclosure Statement under 37 CFR § 1.97 and § 1.98					
	\square	Return Acknowledgment Postcard					

11.



10.	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)				
A.	Enclosed are:				
	(a)	\boxtimes	Computer Readable Copy of the Sequence Listing		
	(b)	\boxtimes	Paper Copy (identical to Computer Readable Copy) of the		
			Sequence Listing		
B.		Enclos	ed is a paper copy of the Sequence Listing. This paper copy and		
		a Com	puter Readable Form thereof are identical with the Computer		
		Readal	ole Form in another application of the Applicant which is fully		
		identif	ied as follows:		
			U.S. Application No.: @@		
			Filed: @@		
			Attorney Docket No.: @@		
		which	is believed to comply with the rules set forth in 37 CFR § 1.821		
		et. seq	Applicants requests pursuant to 37 CFR § 1.821(e) that this		
		Comp	uter Readable Form be used in the present application. Please		
		TRAN	SFER the sequence listing from the parent to this application.		
C.	\boxtimes	Statem	ent under 37 CFR § 1.821(f): The information recorded in		
		compt	iter readable form is identical to the written Sequence Listing.		
D.	\boxtimes	Statem	ent under 37 CFR § 1.821(g) (required when Sequence Listing		
		not sub	omitted at the time of filing under 35 U.S.C. §111(a)) or 37 CFR		
		§1.821	(f) (required when Sequence Listing not submitted at the time of		
		filing u	under the Patent Cooperation Treaty): The submission of the		
		Seque	nce Listing includes no new matter.		
E.	\boxtimes	Amend	lment: Please enter the Sequence Listing into the application.		
Prelin	inary A	Amend	<u>ment</u>		
Prior to	o calcul	ation of	fees, kindly enter:		
\boxtimes	Preliminary Amendment submitted herewith				
	do not enter Preliminary Amendment				



12. Fee payment being made at this time is enclosed:

* Basic filing fee (\$860.00) 860.00 * Claims in Excess of 20 360.00 * (20 @ \$18.00)

(20 @ \$18.00)

Independent Claims in Excess of 3 240.00 (4 @ \$80.00)

* Total Fees enclosed:

\$1460.00

13. The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Account No. 50-0258. This letter is filed in duplicate for accounting purposes.

Respectfully submitted,

Date: February 13, 2001

Arthur E. Jackson Registration No. 34,354

Allen Bloom

Registration No. 29,135 Attorney for Applicant

DECHERT 4000 Bell Atlantic Tower 1717 Arch Street Philadelphia, PA 19103-2793

Fax: (609) 620-3259

Attn: Arthur E. Jackson, Esq.

(609) 620-3254

105886.1.07